Govt may mandate QR codes on vaccines, key drugs to curb counterfeits
Vaccines
, antimicrobials, narcotic drugs and psychotropic substances, and additional
cancer drugs
would have to mandatorily print or affix bar codes or quick response (QR) codes on their labels. This follows the government mulling the possibility of bringing them under Schedule H2 of Drug Rules to track their movement to curb counterfeiting.
Additionally, the government is considering inclusion of details of excipients on every medicine strip for 300 drug formulations that are under Schedule H2. Currently, the labels declare only those active substances added in the formulation.
An excipient is a constituent of a medicine other than the active substances, added in the formulation for a specific purpose. While most excipients are considered inactive, some can have a known action or effect in certain circumstances.
"The
Drug Controller General of India
(DCGI) will hold a meeting this week to deliberate on both the issues," people in the know told ET.
Earlier the drug regulatory authority had included a few cancer drugs to help validate the authenticity of medicines following incidents of refilling of expensive anti-cancer drugs with
counterfeit drugs
. It came to light that criminals in collusion with hospital pharmacies were found refilling empty vials of expensive anti-cancer medicines with counterfeit drugs. These fake drugs were then mixed with genuine stocks and sold to unsuspecting cancer patients, putting their lives at risk.
Live Events
In a bid to weed out spurious drugs, the regulator had made it mandatory for companies to have a barcode on the top 300 brands, so that information such as manufacturing licence and batch number can be accessed upon scanning. These drugs included widely-used analgesics, pain relievers, anti-platelet, vitamin supplements, blood-sugar lowering medicines and contraceptive tablets.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
2 days ago
- News18
Small Drugmakers Supplying Medicines In Rural Areas Under Scrutiny; Centre Calls For Crackdown
Central Drugs Standard Control Organisation has conducted over 1,000 Risk-Based Inspections across the country and asked states/UTs to continue acting after finding non-compliance. Small pharmaceutical companies, especially those supplying medicines in rural areas, have come under regulatory scrutiny, with the Drug Controller General of India (DCGI) directing state officials to closely monitor their activities and ensure accountability. The DCGI has asked states, via state licensing authorities (SLAs) to take strict action against any such marketers found violating quality standards under the Drugs and Cosmetics Rules, 1945. The move comes amid growing concerns over the quality and compliance practices of certain small-scale players in the drug distribution chain. The apex drug regulatory agency has also called for stricter action against the repeated manufacture of spurious and Not of Standard Quality (NSQ) drugs and asked states to keep CDSCO informed of any regulatory actions taken. 'We are still awaiting response on Schedule M compliance and most small players are unable to cope up with quality scrutiny. The government is convinced that without proper oversight, these companies pose a risk to medicine safety in under-served regions," a senior government official privy to the development told News18. The official added that the apex regulatory authority, Central Drugs Standard Control Organisation (CDSCO) has conducted over 1,000 Risk-Based Inspections (RBIs) across the country. 'These inspections have been key in identifying non-compliance among drug manufacturers and strengthening the surveillance framework." The first is adoption of revised Schedule M. The DCGI has asked state officials to begin enforcing updated Good Manufacturing Practice norms for drug production units. Also, it has asked to fix new drug licensing gaps as state licensing officials have been asked to refrain from issuing product licences without proper permissions from DCGI. The officials have also been instructed 'Post risk based inspections action." The states and UTs have been urged to act on the findings and recommendations that emerge from inspections. CDSCO has informed officials to comply with '84AB" in which details of all drug makers and product details must be uploaded and verified on the central online portal to ensure traceability. Also, the state officials will work on building testing lab capacity which has been flagged as a 'critical need."
India Today
3 days ago
- India Today
Karnataka seeks central probe into clinical trial lapses at HCG hospitals
The Karnataka government has written to the Central Drugs Standard Control Organisation (CDSCO), requesting an investigation into alleged irregularities in clinical trials conducted at the Bengaluru-based Healthcare Global Enterprises Ltd (HCG) hospitals. The move follows concerns raised by Justice P Krishna Bhat, a retired judge and former chairperson of the hospital's Institutional Ethics Committee (IEC) regarding patient safety and procedural violations during trial to the media, Karnataka Health Minister Dinesh Gundu Rao said the decision to seek an inquiry stemmed from troubling reports. 'This is based on certain information we saw and received, including some news articles, and then we found out there were some issues. This is a very serious issue, and it has been raised by the ethics committee of HCG Cancer Hospital itself by their own committee, chaired by Justice Krishna Bhat,' he said. He added that the Health Commissioner has already written to the Drug Controller General of India. 'We have asked them to look into the issue and investigate the matter, because it has serious implications regarding clinical trials and related concerns. I do not know what the truth is behind the whole thing, but it must be investigated by a responsible agency, and that is the CDSCO,' Rao BS Ajai Kumar, Founder and Chairman of HCG hospitals, responding to the allegations, issued a statement reiterating the hospital's adherence to all regulatory frameworks. 'We have noticed some unverified information about HCG, a pioneer in cancer care in India and Africa. We assure you that we strictly adhere to all guidelines set by regulatory authorities, including the Drug Controller General of India (DCGI) and the Indian Council of Medical Research (ICMR). Currently, we are successfully conducting a significant number of trials with utmost transparency, prioritising patient safety, approved by our Ethics Committee. Our commitment to delivering exceptional care remains unwavering,' Dr Ajai Kumar said on behalf of Healthcare Global Enterprises of the concerns were outlined in a letter dated June 30, 2025, by Health and Family Welfare Department Commissioner Sivakumar K B, who highlighted issues raised by Justice Bhat. These included unchecked conflicts of interest and irregularities in patient enrolment during trials, as reported by South letter, addressed to the Drugs Controller General of India, stated: 'These concerns have been flagged by none other than the chairperson of the institutional ethics committee, who has subsequently resigned.' It added: 'These lapses, if proven, will undermine the strict ethical principles laid down by the CDSCO, Department of Health Research, Indian Council of Medical Research, and global regulatory bodies like the World Health Organisation, which mandate the highest standards of patient safety and ethical conduct in clinical trials.'advertisementThe Commissioner described the matter as 'of serious concern' and called for a thorough probe into the allegations of 'unfair clinical trials being conducted at Bengaluru's HCG.'Justice Bhat had raised multiple concerns with then Chief Executive Officer Raj Gore and former Medical Director Dr Harish Reddy following discussions in several ethics committee meetings, in a March 5, 2025, letter, which was accessed by South of the most serious issues was a potential conflict of interest involving Dr Sathish, who allegedly served as both principal investigator and in a supervisory role as Director of the Ethics Committee. Justice Bhat wrote that this dual role posed ethical risks, including compromised patient safety, dilution of inclusion criteria, and resistance to procedural letter noted that although there is no formal post of 'Director of Clinical Trials' within ethics committees, institutions may appoint someone as 'Director of Clinical Trial Development' at the corporate level, typically endorsed by top leadership. Justice Bhat stated that during the 18 committee meetings he attended, the individual never clarified that he was not serving in such a dual concerns listed in the letter included rushed presentations, bypassing informed review processes, an excessive number of poorly explained trial proposals, and direct communication between the investigator and sponsors, which could open the door to commercial bias and protocol manipulation.- Ends IN THIS STORY#Karnataka#Bengaluru
Mint
3 days ago
- Mint
Bigger fonts, clearer tags: How the drug regulator is looking to redesign hard-to-read medicine labels
New Delhi: Ever squinted at a medicine strip trying to find the expiry date, or popped a pill without knowing whether it's branded or generic? You're not alone. India's top drug regulator is stepping in to change that. The Drug Controller General of India (DCGI) is working on a nationwide overhaul of medicine packaging and labelling norms. The goal is to make expiry dates and batch numbers easier to read, reduce confusion between generic and branded drugs, and help patients, make better-informed choices, two government officials aware of the matter said. As part of the proposed changes, manufacturers may soon be required to use larger fonts, ditch shiny packaging that reflects light and obscures print, and print expiry dates in more than one place to prevent vital information from being torn off. There's also a plan to introduce a universal symbol to clearly distinguish generic medicines from branded ones. The regulator had received several complaints regarding the difficulty in differentiating between cheaper generic drugs and their branded counterparts, and consequently, the pricing comparison. "The drug regulator has received various complaints and demands from the consumers regarding the labelling of medicinal products such as tiny font size of the letters printed on the drug packaging, shiny labels, the expiry date of the medicines getting torn while taking out the medicine, and demand for universally recognised symbol on the generic medicines that will distinguish it from the branded medicines," said one of the officials cited above requesting anonymity. A sub-committee, set up by the DCGI, is reviewing the proposals and is expected to submit its report soon, the second official said. The committee is also examining ways to incorporate these changes under the Drugs and Cosmetics Rules, 1945, which governs the quality of drugs manufactured, imported, and sold in the country. Queries sent to the health ministry on Monday and DCGI spokesperson on Tuesday remained unanswered till press time. Also Read: India's drug regulator plans overhaul of Schedule H for prescription medicines Branded vs generic While both generic and branded medicines contain the same active ingredient and are expected to have the same therapeutic effect, their key differences lie in cost, brand recognition, and patent status. Branded medicines such as a well-known painkiller, often carry a higher price tag due to the research, development, and extensive marketing by the innovator company. Generic medicines, on the other hand, are typically much cheaper (often 80-85% less) because they are manufactured after the original drug's patent expires, eliminating the need for costly R&D and marketing. For instance, if 'PainRelief Pro' is a popular branded drug for headaches, its generic equivalent, say 'Paracetamol 500mg', will offer the same relief at a fraction of the cost. But customers often miss this. They ask for affordable, quality medicines but are often unaware of generic alternatives, said Rajiv Singhal, president and General Secretary of the All India Organization of Chemists and Druggists (AIOCD) representing 1.2 million members in the country. He called for expiry and batch details to be printed in clearer, larger fonts in multiple places to prevent accidental torn off. 'If this regulation comes into play, companies will have to mandatorily follow," he said, emphasizing the importance of regulatory enforcement. The development assumes significance given that India holds the distinction of being the world's largest supplier of generic drugs, accounting for approximately 20% of the global supply and manufacturing around 60,000 generic brands across 60 therapeutic categories. Mint had earlier reported that DCGI was considering Braille labelling on drug packaging to support the 4.95 million blind and 70 million visually impaired people in India. Global standards Globally, drug labels tend to be much simpler. Dr. Viranchi Shah, national spokesperson for the Indian Drugs Manufacturers Association (IDMA), said Indian medicine strips are detailed compared to their international counterparts. For example, international labels often only state the tablet's name, omitting details like coating information or the explicit phrase "to be sold on the prescription of registered medical practitioners." Instead, the "Rx" symbol is commonly used to indicate a prescription requirement, with its absence signifying an over-the-counter (OTC) drug. The extensive information and specific font size requirements on Indian labels are seen as cumbersome, leading to substantial inventory costs and a significant financial burden on companies for redesigning packaging, Shah said. He said that the industry is open to changes for the greater good and informed that IDMA had previously submitted its representation to the DCGI years ago, suggesting simplified labelling. He said that a key hurdle to such changes is the significant inventory held by pharmaceutical companies. Changes to labelling would require a phased approach to avoid disruption. 'Any future changes, whenever and however implemented, should consider suggestions from both patients and the industry, and be introduced in a phased manner to minimize disruption." This step will empower patients and enhance transparency in the Indian pharmaceutical market, said Nikkhil K. Masurkar, CEO, Entod Pharmaceuticals. The current lack of visual cues on packaging, he said, often leaves patients unaware of generic alternatives. The government's Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) may also benefit from the labelling overhaul. PMBJP operates over 17,000 Janaushadhi Kendras across India to offer quality generic medicines at affordable rates. Also Read: Centre orders thorough safety review of painkiller Nimesulide for adults India's pharmaceutical market, meanwhile, continues to expand. According to Pharmarack, the Indian Pharmaceutical Market (IPM) reached ₹19,720 crore in sales for May 2025, showing a 7.2% YoY growth. On a moving annual total (MAT) basis, the industry posted ₹2.29 trillion, reflecting an 8.1% annual growth and 9.8% CAGR. While pharma companies may face some logistical costs in updating their packaging, the industry believes these are manageable and worth the impact on patient safety, affordability, and transparency.
